Comparative Effectiveness of Carvedilol Versus Other Nonselective β-Blockers in Cirrhosis: A Clinical Review
Highlights
- Carvedilol reduces the risk of major cirrhosis decompensation events more effectively than nadolol and propranolol.
- Meta-analyses and randomized trials reveal carvedilol’s superior reduction of hepatic venous pressure gradient (HVPG) in cirrhotic patients.
- Real-world observational studies confirm carvedilol’s protective effect against variceal hemorrhage, ascites, spontaneous bacterial peritonitis (SBP), and hepatorenal syndrome (HRS).
- Carvedilol’s dual beta- and alpha-1 adrenergic blockade provides mechanistic advantages in managing portal hypertension.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.